Cas9-GFP/dual-BA-sgRNA efficiently disruptsBCR-ABL at the genomic sequence and gene expression levels in leukemia cells, leading to blockade of the BCR-ABL tyrosine kinase signaling pathway and disruption of its downstream molecules, followed by cell proliferation inhibition and cell apoptosis induction. Here, ABL1 is linked to leukemia.